Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
J Cell Mol Med ; 28(8): e18245, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-38613356

RESUMEN

Diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype (H3/IDH-wt-pHGG) is a newly defined entity amongst brain tumours, primarily reported in children. It is a rare, ill-defined type of tumour and the only method to diagnose it is DNA methylation profiling. The case we report here carries new knowledge about this tumour which may, in fact, occur in elderly patients, be devoid of evocative genomic abnormalities reported in children and harbour a misleading mutation.


Asunto(s)
Neoplasias Encefálicas , Glioma , Sustancia Blanca , Anciano , Femenino , Humanos , Niño , Neoplasias Encefálicas/diagnóstico por imagen , Neoplasias Encefálicas/genética , Genómica , Lóbulo Occipital/diagnóstico por imagen
2.
Genes Chromosomes Cancer ; 61(12): 734-739, 2022 12.
Artículo en Inglés | MEDLINE | ID: mdl-35949061

RESUMEN

Most available molecular data on pancreatic acinar cell carcinoma (PACC) are provided by studies of adult cases. BRAF, RAF1, or RET rearrangements have been described in approximately 30% of cases. To the best of our knowledge, only seven cases with molecular data have been reported in pediatric PACC. We report here the comprehensive study of a pancreatic-type ACC from a 6-year-old patient. We detected an AGAP3::BRAF fusion. This result showing a BRAF rearrangement demonstrates a molecular link between adult and pediatric PACC. Moreover, it identifies AGAP3, a gene located at 7q36.1 that encodes a major component of the N-methyl-d-aspartate (NMDA) receptor signaling complex, as a partner gene of BRAF. The variability of BRAF partners is consistent with a driver role of BRAF alterations in PACC. The identification of such alterations is noteworthy for considering the use of MEK inhibitors in metastatic cases. We did not detect associated genomic instability. The better outcome of pediatric cases might be related to their stable genomic background.


Asunto(s)
Carcinoma de Células Acinares , Neoplasias Pancreáticas , Adulto , Carcinoma de Células Acinares/genética , Carcinoma de Células Acinares/patología , Niño , Humanos , Quinasas de Proteína Quinasa Activadas por Mitógenos/genética , Mutación , N-Metilaspartato/genética , Neoplasias Pancreáticas/genética , Neoplasias Pancreáticas/patología , Proteínas Proto-Oncogénicas B-raf/genética , Neoplasias Pancreáticas
3.
BJU Int ; 129(1): 80-92, 2022 01.
Artículo en Inglés | MEDLINE | ID: mdl-34107167

RESUMEN

OBJECTIVES: To investigate the role of cancer-associated fibroblasts (CAFs) in clear cell renal cell carcinoma (ccRCC) with respect to tumour aggressiveness, metastasis development, and resistance to anti-angiogenic therapy (vascular endothelial growth factor receptor-tyrosine kinase inhibitors [VEGFR-TKI]). PATIENTS AND METHODS: Our study involved tissue samples from three distinct and independent cohorts of patients with ccRCC. The presence of CAFs and tumour lymphangiogenesis was investigated, respectively, by transcriptional signatures and then correlated with tumour development and prognosis. The effect of these CAFs on tumour cell migration and VEGFR-TKI resistance was analysed on co-cultures of ccRCC cells with CAFs. RESULTS: Results from our cohorts and from in silico investigations showed that VEGFR-TKI significantly increase the number of CAFs in tumours. In the same populations of patients with ccRCC, the proportion of intra-tumoral CAFs correlated to shorter disease-free and overall survival. The presence of CAFs was also correlated with lymphangiogenesis and lymph node metastasis. CAFs increased the migration and decreased the VEGFR-TKI-dependent cytotoxic effect of tumour cells. CONCLUSIONS: Our results show that VEGFR-TKI promote the development of CAFs, and CAFs favour tumour aggressiveness, metastatic dissemination, and resistance to treatment in ccRCC. CAFs could represent a new therapeutic target to fight resistance to treatment of ccRCC. Targeting CAF and immunotherapies combination are emerging as efficient treatments in many types of solid tumours. Our results highlight their relevance in ccRCC.


Asunto(s)
Fibroblastos Asociados al Cáncer/patología , Carcinoma de Células Renales/patología , Resistencia a Antineoplásicos , Neoplasias Renales/patología , Neovascularización Patológica/patología , Actinas/genética , Adulto , Anciano , Anciano de 80 o más Años , Inhibidores de la Angiogénesis/metabolismo , Inhibidores de la Angiogénesis/uso terapéutico , Animales , Antineoplásicos/metabolismo , Antineoplásicos/uso terapéutico , Biomarcadores de Tumor/genética , Fibroblastos Asociados al Cáncer/efectos de los fármacos , Fibroblastos Asociados al Cáncer/fisiología , Capilares/patología , Carcinoma de Células Renales/genética , Carcinoma de Células Renales/secundario , Carcinoma de Células Renales/cirugía , Diferenciación Celular/efectos de los fármacos , Línea Celular Tumoral , Movimiento Celular , Supervivencia sin Enfermedad , Endopeptidasas/genética , Femenino , Humanos , Neoplasias Renales/genética , Neoplasias Renales/terapia , Linfangiogénesis , Metástasis Linfática , Masculino , Proteínas de la Membrana/genética , Ratones , Persona de Mediana Edad , Terapia Neoadyuvante , Neovascularización Patológica/tratamiento farmacológico , Nefrectomía , Estudios Retrospectivos , Sunitinib/metabolismo , Sunitinib/uso terapéutico , Tasa de Supervivencia , Transcriptoma
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA